Paratek Pharmaceuticals has reported positive safety and efficacy data from a Phase III clinical trial (OPTIC) of its investigational antibiotic, omadacycline, for community-acquired bacterial pneumonia (CABP).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Omadacycline is being developed as a once-daily, broad-spectrum empiric monotherapy in intravenous (IV) and oral formulations.

The results showed that the investigational antibiotic is well-tolerated and actively targets clinically important typical and atypical CABP pathogens.

OPTIC is designed to compare the safety and efficacy of omadacycline with moxifloxacin in 774 adults with CABP.

Omadacycline was found to be effective in patients with most commonly isolated pathogens such as multi-drug resistant Streptococcus pneumoniae.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“The potent activity observed in the microbiology study supports previously reported in-vitro data, demonstrating that omadacycline is broadly active against multiple CABP pathogens, including resistant pathogens.”

Paratek Pharmaceuticals president chief operating officer and chief medical officer Evan Loh said: “These microbiology data add to our growing understanding of the clinical and in-vitro activity of omadacycline, and lay a foundation for clinicians for its potential use in the CABP setting where microbiological confirmation of infection is difficult and a pathogen is only identified in less than 10% of patients.

“The potent activity observed in the microbiology study supports previously reported in-vitro data, demonstrating that omadacycline is broadly active against multiple CABP pathogens, including resistant pathogens.”

The OPTIC trial met the primary endpoint of statistical non-inferiority (NI) in the intent-to-treat (ITT) population at the early clinical response (ECR) 72-120 hours following initiation of treatment.

Paratek further reported that omadacycline demonstrated a consistent safety and efficacy profile during three sub-analyses of Phase III OASIS-1 trial conducted for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in subjects with comorbid conditions.

Image: Lungs with community-acquired pneumonia. Photo: courtesy of Jtechr.